Exhibit 10.30

 

AMENDMENT # 5

to the Research, Option and License Agreement

dated September 29, 1994

 

This Amendment, dated this 23rd day of September, 2002, is by and between Œ
VICAL INCORPORATED, a Delaware Corporation (“VICAL”), having a place of business
located at 9373 Towne Centre Drive, Suite 100, San Diego, California 91212, USA,
 AVENTIS PASTEUR, a French Société Anonyme (“AvP”), having a registered head
office located at 2 avenue Pont Pasteur, 69007 Lyon, France, and Ž AVENTIS
PASTEUR Limited, a company organized and existing under the laws of the Province
of Ontario, Canada (“AvP-Canada”) and having its principal place of business at
Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4.

 

WHEREAS, VICAL and AvP entered into a Research, Option and License Agreement
(“the Agreement”) as of September 29, 1994, as amended by Amendment #1 dated as
of September 29, 1994, by Amendment # 2 dated January 26, 1996, by Amendment # 3
dated as of April 15, 1996, and by Amendment # 4 dated December 7, 2001
(“Amendment # 4”) under which AvP was granted Options in the Field of
Immunotherapeutic vaccines against cancer in humans containing the [***] and to
obtain an exclusive license under certain Patent Rights and certain associated
technologies owned by or licensed to VICAL; and

 

WHEREAS, VICAL informed AvP of its interest in reacquiring the rights related to
[***]; and

 

WHEREAS, according to Amendment # 4, AvP’s Option Period will not expire before
[***]; and

 

WHEREAS, AvP agrees to return its rights to [***] to VICAL;

 

NOW, THEREFORE, the parties agree to amend the Agreement as follows :

 

1.          VICAL hereby requests that AvP abandons its rights to [***] before
the end of the Option Period (as defined in Amendment # 4).

 

2.          AvP hereby agrees to abandon the Option rights with respect to [***]
(as described in point 3. of Amendment # 4), effective immediately.

 

3.          In consideration of the reversion of rights, as soon as practicable
upon execution of this Amendment # 5, VICAL will:

•             Refund to AvP-Canada the USD [***] paid  after execution of
Amendment # 4; and

 

--------------------------------------------------------------------------------

[***] Confidential material redacted and separately filed with the Commission.

 

--------------------------------------------------------------------------------

 

•             Pay to AvP an additional USD [***] for AvP’s administrative
efforts since execution of Amendment # 4.

 

4.          Additionally, VICAL hereby offers to AvP an Option to obtain an
exclusive, worldwide, royalty bearing license to an available cancer specific
antigen (antigen to be identified by a GenBank accession number) under the same
terms and conditions as Amendment #4.  Such Option shall expire [***] following
execution of the present Amendment #5. For the purpose of this Amendment #5,
“available cancer specific antigen” shall mean a cancer specific antigen that:

(i)    VICAL is not pursuing either alone or with a Third Party; OR

(ii)   VICAL has not granted rights to a Third Party.

 

5.          Any provision of the Agreement not modified by this Amendment # 5
shall remain unchanged. Capitalized terms in this Amendment # 5 shall have the
meaning set forth in the Agreement unless otherwise specified.

 

IN WITNESS WHEREOF, the parties hereto have had this Amendment # 5 executed by
their authorized representatives as set forth below.

 

VICAL INCORPORATED

AVENTIS PASTEUR LIMITED

 

 

 

 

By :

/s/ VIJAY SAMANT

 

By :

/s/ MARK LIEVONEN

 

 

Vijay SAMANT

 

Mark LIEVONEN

 

President and C.E.O.

 

President

Date : 9/23/02

Date : 10/18/02

 

 

AVENTIS PASTEUR S.A.

 

 

 

 

 

By :

/s/DAVE WILLIAMS

 

By :

/s/ JIM TARTAGLIA

 

 

Dave WILLIAMS

 

Jim TARTAGLIA

 

President and CEO

 

Vice-President Research

Date : 10/7/02

Date : 10/21/02

 

 

[***] Confidential material redacted and separately filed with the Commission.

 

2

--------------------------------------------------------------------------------